Cite
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
MLA
Sangro, Bruno, et al. “Association of Inflammatory Biomarkers with Clinical Outcomes in Nivolumab-Treated Patients with Advanced Hepatocellular Carcinoma.” Journal of Hepatology, vol. 73, no. 6, Dec. 2020, pp. 1460–69. EBSCOhost, https://doi.org/10.1016/j.jhep.2020.07.026.
APA
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., Tang, H. (Tracy), Shen, Y., Tschaika, M., Neely, J., & El-Khoueiry, A. (2020). Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 73(6), 1460–1469. https://doi.org/10.1016/j.jhep.2020.07.026
Chicago
Sangro, Bruno, Ignacio Melero, Samir Wadhawan, Richard S. Finn, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Thomas Yau, et al. 2020. “Association of Inflammatory Biomarkers with Clinical Outcomes in Nivolumab-Treated Patients with Advanced Hepatocellular Carcinoma.” Journal of Hepatology 73 (6): 1460–69. doi:10.1016/j.jhep.2020.07.026.